

## TITLE PAGE

**Title of the article:** Weight loss with different types of fasting in patients with type two diabetes and hypertension: a randomized clinical trial.

**Running head:** Different Types of Fasting for T2D and CVD

## AUTHORS

**Kuat OSHAKBAYEV**\* <sup>1, 10</sup> (corresponding author), MD, PhD, DMSc, professor; **Alisher IDRISOV** <sup>2</sup>, MD, PhD, DMSc; **Altay NABIYEV** <sup>3</sup>, MD, PhD; **Kenzhekzy MANEKENOVA** <sup>4</sup>, MD, PhD, DMSc, professor; **Gulnara BEDELBAYEVA** <sup>5</sup>, MD, PhD, DMSc, associate professor; **Aigul DURMANOVA** <sup>6</sup>, MD, PhD, DMSc, associate professor; **Gani KUTTYMURATOV** <sup>7</sup>, MD, PhD; **Nurzhan BIKHANOV** <sup>8</sup>, MD, PhD; **Bibazhar DUKENBAYEVA** <sup>9, 10</sup>, MD, PhD, associate professor.

### Affiliations of authors:

<sup>1\*</sup> University medical center, Clinical academic department for Internal Medicine. Street Syganak 46, 010000, Astana city, the Republic of Kazakhstan. Mob. phone: +7-701-3999394; e-mails: [okp.kuat@gmail.com](mailto:okp.kuat@gmail.com); [kuat.oshakbayev@umc.org.kz](mailto:kuat.oshakbayev@umc.org.kz). ORCID: <http://orcid.org/0000-0003-4883-295X>

<sup>2</sup> Astana Medical University, Department of Family Medicine, Street Beibitshilik 49a, Astana city, the Republic of Kazakhstan. Tel.mob.: +7-7015140583; E-mail: [aliser73@mail.ru](mailto:aliser73@mail.ru). ORCID: 0000-0001-9085-9836

<sup>3</sup> University medical center, Clinical academic department for Internal Medicine. Street Syganak, 46, 010000, Astana city, the Republic of Kazakhstan. Mob. phone: +7 701 908 2725; e-mail: [a.nabiyev@umc.org.kz](mailto:a.nabiyev@umc.org.kz). ORCID: 0000-0002-0925-3528

<sup>4</sup> Astana Medical University, Department of Pathology, Street Beibitshilik 49a, Astana city, the Republic of Kazakhstan. Mob.: +77014014728; Email: [kena\\_31@mail.ru](mailto:kena_31@mail.ru).  
ORCID: 0000-0001-9551-1898

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- <sup>5</sup> Asfendiyarov Kazakh National Medical University, Faculty of postgraduate education.  
Street Tole Bi, 94, Almaty city, 050000, the Republic of Kazakhstan. Tel.mob.:  
+77772281581; E-mail: [bedelbaeva@mail.ru](mailto:bedelbaeva@mail.ru). ORCID: [0000-0002-3484-969X](https://orcid.org/0000-0002-3484-969X)
- <sup>6</sup> University medical center, Clinical Academic Department for Internal Medicine. Street  
Syganak 46, 010000, Astana, the Republic of Kazakhstan. Tel.mob.: +7-777 263  
7736. E-mail: [Aigul.Durmanova@umc.org.kz](mailto:Aigul.Durmanova@umc.org.kz); ORCID: [0000-0003-2006-7803](https://orcid.org/0000-0003-2006-7803).
- <sup>7</sup> University medical center, Clinical Academic Department for Surgery. Street Syganak  
46, 010000, Astana, the Republic of Kazakhstan. Tel.mob.: +7-701-8812206; e-mail:  
[gani.kt@umc.org.kz](mailto:gani.kt@umc.org.kz) ; [aiger2000@mail.ru](mailto:aiger2000@mail.ru) . ORCID: [0000-0003-4642-1452](https://orcid.org/0000-0003-4642-1452)
- <sup>8</sup> University medical center, Clinical Academic Department for Surgery. Street Syganak  
46, 010000, Astana, the Republic of Kazakhstan. Tel.mob.: +7-7711030143; E-mail:  
[n.bihanov@umc.org.kz](mailto:n.bihanov@umc.org.kz). ORCID: [0000-0002-0890-4763](https://orcid.org/0000-0002-0890-4763)
- <sup>9</sup> Astana Medical University, Department of Pathology, Street Beibitshilik 49a, Astana  
city, the Republic of Kazakhstan. Tel.mob.: +7-7013999141; E-mail:  
[dukenbaeva74@gmail.com](mailto:dukenbaeva74@gmail.com). ORCID: [0000-0002-2129-0460](https://orcid.org/0000-0002-2129-0460).
- <sup>10</sup> ANADETO medical center, Street Kerey, Zhanibek khans 22, Astana city, 010000, the  
Republic of Kazakhstan.

**Corresponding Author:** Kuat Oshakbayev. University medical center

(<https://umc.org.kz>), Clinical academic department for Internal Medicine. The Republic  
of Kazakhstan, 010000, Astana city, str. Syganak 46. Mob. phone: +7-7013999394.

Emails: [okp.kuat@gmail.com](mailto:okp.kuat@gmail.com); [kuat.oshakbayev@umc.org.kz](mailto:kuat.oshakbayev@umc.org.kz)

**Word counts** (introduction to conclusion): 3340

**Number of Tables:** 1

**Number of Figures:** 1

**Number of References:** 68.

## DECLARATION

The study was carried out in the Republic of Kazakhstan from March 22, 2023, through April 20, 2023. Participants were recruited gradually as they arrived at the Diagnostic Center of University Medical Center (Astana) and ANADETO Medical Center.

**Ethics approval and consent to participate.** The Ethical Committee of the University Medical Center (phone: +7 7172 69-25-86; Web: <https://umc.org.kz/en/?ethics-commission=post-2>; Email: [mirgul.bayanova@umc.org.kz](mailto:mirgul.bayanova@umc.org.kz)) approved the study (approval protocol #6 of 14.11.2022; monitoring and re-approval protocol #7/ПЭ, October-11-2023, project #2023/01-24. Board Affiliation: University Medical Center).

The committee confirms that all methods were performed in accordance with the Declaration of Helsinki and guidelines of the Council for International Organizations of Medical Sciences (CIOMS) and that informed consent was obtained from all participants.

## ABSTRACT

1 **Background.** The coexistence of type two diabetes (T2D) and cardiovascular diseases  
2 (CVD) in patients with overweight increases the risk of macro-vascular complications.  
3 Some studies are controversial of the results of Ramadan fasting (RF) in patients  
4 T2D+CVD.  
5 **Objective:** To compare different RF (antique and modern) on anthropometric, glycemic,  
6 blood pressure (BP), lipids, heel bone mineral density (HBMD), and ejection fraction  
7 (EF) in patients with T2D+CVD.  
8 **Methods.** An open, 60-day, controlled, single-center, randomized clinical trial included  
9 51 patients (29 women) with T2D+CVD: 26 in Main (antique RF); 25 in Controls  
10 (modern RF). *Primary endpoints:* weight loss, fasting blood glucose and, blood insulin,  
11 BP. *Secondary endpoints:* blood lipids, HBMD, and EF.

12 **Results.** Patients in Main lost weight  $-8.02$  kg ( $P<0.0001$ ), in Controls lost weight  $-2.67$   
13 kg ( $P<0.025$ ); BMI in Main significantly decreased ( $P<0.0001$ ), but in Controls did not  
14 significantly decrease ( $P>0.025$ ). During a 30-day follow-up, Main did not regain weight  
15 and WC; but Controls regained weight and WC.

16 In Main BP, all glycemic parameters (fasting glucose, immunoassay insulin, HOMA-IR),  
17 lipids (cholesterol, triglyceride, HDL), HBMD, and EF in patients with and without heart  
18 failure (HF) were significantly normalized at 30-day RF ( $P<0.0001$ ). In Controls BP and  
19 all glycemic parameters significantly improved but they did not achieve normal  
20 ( $P>0.025$ ). In Controls HBMD and EF in patients with HF did not change ( $P>0.025$ ).

21 At 30-day follow-up, glycemic, BP, lipids, HBMD, and EF parameters did not  
22 significantly change in Main; but in Controls they worsened as weight regained.

23 **Conclusion.** Both the RF methods allowed weight loss, but antique RF led to markedly  
24 weight loss and significant positive change in glycemic, BP, lipids, bone mineralization,  
25 and EF in patients with T2D+CVD; the antique RF allowed patients to stop taking  
26 medications. The duration of the positive results depended on the maintenance of the  
27 achieved weight loss on RF.

**Trial Registration:** ClinicalTrials.gov NCT06410352 (05/08/2024):

28 <https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000EG8K&selectact>  
29 [ion=Edit&uid=U0006MBT&ts=139&cx=bhsvd1](https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000EG8K&selectaction=Edit&uid=U0006MBT&ts=139&cx=bhsvd1)

30 **Keywords:** Type 2 diabetes mellitus; hypertension; heart failure; Ramadan fasting;  
31 weight loss; insulin, lipids, osteoporosis.

## 32 **1 INTRODUCTION**

33 Numerous studies show that the most common risk factor for developing type two  
34 diabetes mellitus (T2D), hypertension, heart failure (HF), and atherosclerosis is  
35 overweight/obesity. [1-4] T2D with cardiovascular diseases (CVD) are the leading cause  
36 of mortality/morbidity worldwide. [5, 6]

37 Hypertension and T2D are independently associated with impaired left ventricular  
38 diastolic function, independent of the effect of overweight/obesity and other covariates.  
39 [7, 8] HF is positively associated with overweight and T2D. [8, 9] The coexistence of  
40 hypertension and T2D increases the risk of macro-vascular complications and it is  
41 responsible for a high cardiovascular mortality. [10, 11] Early and aggressive treatment  
42 of the patients is therefore mandatory in diabetic and pre-diabetic groups. [12]  
43 Pharmacologic and biologic treatment of T2D and CVD has yielded positive results,  
44 however, these results were accompanied by numerous side effects. [5, 13, 14]  
45 Establishment of reliable, safe, and natural methods for the treatment of the non-  
46 communicable diseases, particularly in patients with T2D, hypertension, and HF, are  
47 required.  
48 Several studies showed that weight loss improved left ventricular function in patients  
49 with elevated blood pressure (BP) and T2D, [1, 15, 16], and decreased mortality and  
50 morbidity from HF. [17-19]  
51 Despite adverse association between obesity and the non-communicable diseases,  
52 numerous studies have documented an obesity paradox, in which obese people with  
53 established CVD, including hypertension, coronary heart disease, and HF, have a better  
54 prognosis than patients who are not overweight or obese. [20-22]  
55 The cluster of T2D, CVD, dyslipidemia, and hypertension have also been associated  
56 with increased risk of low bone mineral density, [23, 24] together they may lead to  
57 macro-vascular catastrophe. [24, 25]  
58 In countries where the official religion is Islam, there are large populations of Muslims  
59 with T2D and CVD who fast during Ramadan fasting (RF). RF lowers body weight, body  
60 fat percentage and body mass index (BMI). [26, 27] Changes in the pattern of meal and  
61 fasting during this long-fasting hours could lead to weight loss and improve glycemic  
62 and cardiovascular parameters. [26-28]

63 Some studies are controversial of the results of RF in patients T2D and CVD [26, 29],  
64 and it may cause a transient worsening of glycemic control that might be associated  
65 with weight gain [30, 31] and/or exacerbation of chronic diseases during RF. [32, 33]  
66 The majority of patients with stable cardiac illness can opt for RF safely. [26, 34]  
67 However, the effects of RF on cardiovascular outcomes and T2D remain uncertain. The  
68 relationship between weight reduction and improvement in health parameters in patients  
69 with T2D, serious CVD is not thoroughly studied.

70 Results of many studies suggest that the effect of RF on glycemic and/or cardiovascular  
71 parameters depends on the amount of weight loss during the RF. [26, 28, 35] We  
72 recently demonstrated weight loss with positive clinical results in overweight/obese  
73 patients with T2D and CVD. [36-38]

74 Ancient civilizations had another culture of RF than modern RF. [31, 39] For instance,  
75 antique fasting modes (Shabbat, Ramadan, Christian) prohibited eating meat and fatty  
76 foods. [39-41] It is assumed that modern RF differ from ancient RF. Antique people  
77 could lose more weight during RF than modern people. Ancient people did not have  
78 access to excess food consumption like modern people. The aim of this study was to  
79 compare the results of different RFs (ancient and modern) on the anthropometric,  
80 glycemic, BP, lipids, and ejection fraction (EF) in patients with T2D and CVD.

## 81 **2 METHODS**

82 **2.1 Study Design:** An open, 60-day, controlled, single-center, randomized clinical trial.

83 **2.2 Participants** The study screened in total 96 participants, and in the intention-to-treat  
84 analysis enrolled for eligibility 61 adult treatment-seeking patients aged 35 to 65 years  
85 with T2D and hypertension; 35 were excluded due to inclusion criteria. From the  
86 enrolled 61 patients five patients were excluded due to noncompliance with the  
87 inclusion/exclusion criteria as explained below. Finally, 56 patients were included in the  
88 study. (**Figure 1**)

89 The patients were randomly divided into two groups: in Experimental group (Main) 28  
90 patients; in Control group (Controls) 28 patients. Main group were on ancient (antique)  
91 RF, and Controls were on modern RF (conventional, traditional).

92 Five of the remaining 56 patients (7.1%) dropped out before study completion: two  
93 refused the RF for 2-3 days after starting, three were excluded due to noncompliance.  
94 Thus, 51 patients (29 women, 39 patients  $\geq 50$  years old, all Asian ethnicity) were  
95 included for the final analysis: in Main 26 patients; in Controls 25 patients. After 30-day  
96 of RF all patients were observed in 30-day followed-up. (**Figure 1**) In Main 14 patients  
97 and in Controls 13 patients had HF in their medical records and anamnesis with  
98 reduced EF  $< 55\%$ ; I-II stages of the NYHA functional classification.

99 In total were 10 visits: Visit 1-2 (pre-baseline and baseline) – informed consent, blood  
100 samples, anthropometry & BP, ultrasound imaging & densitometry; Visits 3-5 (every  
101 week during RF) – medical evaluation & BP; Visit 6 (after the end of RF) –  
102 anthropometry & BP, blood samples, ultrasound & densitometry; Visits 7-9 (every week  
103 during 30-day of follow-up after RF) – medical evaluation & BP; Visit 10 (after follow-up  
104 period) – anthropometry & BP, blood samples, ultrasound & densitometry.

105 A combination of in-person conversations and telephone calls were conducted during  
106 the whole 60-day study period. During all visits, RF patients were closely followed and  
107 motivated (answers to questions, consultations, advice) by the clinical nutrition team to  
108 ensure weight loss in both the Main and Control groups.

109 **Inclusion criteria:** 1) written informed consent; 2)  $35 \leq$  age  $< 65$  years old; 2) BMI  $\geq 23$   
110  $\text{kg/m}^2$ ; 3) diagnosis of T2D and hypertension  $\geq 3$  years and treatment with non-hormonal  
111 conventional pharmacological medications; 4) any level of triglycerides, cholesterol; 5)  
112 weight loss for 30-day RF, and 30-day of follow-up periods.

113 **Exclusion criteria:** 1) age  $< 35$  or  $\geq 65$  years old; 1) insulin-dependent T2D and  
114 uncontrolled high BP; 2) patients after bariatric surgery; 3) patients taking



115 gastrointestinal lipase inhibitors, etc.; 4) presence of acute infection diseases or  
116 exacerbation of chronic diseases; 5) EF <40%; 6) history of alcohol consumption >30  
117 g/day within the past 5 years; 7) malignancy within the past 5 years; kidney failure;  
118 gestation/lactation; hereditary diseases; or known hypersensitivity to any substances.

119 **Randomization.** An independent statistician unconnected with clinical practice used  
120 simple randomization based on a single sequence of random assignments. A simple  
121 randomization method was tossing a coin. In the two treatment groups (Main vs.  
122 Controls), the side of the coin (heads/tails for Main/Controls as a random number  
123 generator) determines the assignment of each patients.

124 **Outcome measures:** *Primary endpoints:* weight loss, fasting blood glucose, blood  
125 insulin, systolic/diastolic BP (SBP/DBP). *Secondary endpoints:* blood lipids, heel bone  
126 mineral density (HBMD), and EF.

127 **Interventions.** Main group adhered to fasting on ancient RF; who strictly adhered to  
128 two principles of nutrition during ancient RF: 1) “no blood, no smell of fat” which means  
129 “don’t eat meat and don’t eat fatty foods” in the allotted time; 2) the ‘Sehri time’ (a meal  
130 eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (dried  
131 apple, dates, and persimmon). After 30-day ancient RF, Main was followed by a 30-day  
132 time-restricted feeding (TRF) mode 20:4, wherein individuals fast for 20 hours with 4-  
133 hour window for caloric intake; or taking one meal a day (in the evening) with usual  
134 regular meal including meat and fatty foods. [42, 43]

135 Controls adhered to fasting on modern RF (conventional standard RF) with: 1) no  
136 restrictions to eat meat and/or fat meal in the allotted time; 2) no food restrictions to the  
137 ‘Sehri time’ and ‘Iftar time’ (a meal eaten after sunset). After a 30-day modern RF,  
138 Controls switched to a regular diet.

139 Both groups at baseline received conventional anti-diabetic, anti-hypertensive,  
140 pathogenetic, and symptomatic pharmacologic therapy. T2D was treated with



141 Metformin, Sulfonylurea, GLP-1 agonists (exenatide, liraglutide), Glitazones in different  
142 combinations; hypertension was treated with beta-blockers, calcium channel blockers,  
143 diuretics, SGLT-2 Inhibitors (empagliflozin, canagliflozin) in different combinations. Both  
144 groups adhered to walking at least 3,000 steps/day, and sexual self-restraint.

145 *Blinding of investigators.* All patients were under the supervision of only four physicians  
146 from the clinical nutrition group; patients in both comparison groups were under the  
147 supervision of the same physicians without assignment to any patient group; different  
148 patients in the comparison groups were under the supervision of the same physician,  
149 and vice versa, the same patients in different comparison groups were under the  
150 supervision of different physicians.

### 151 **2.3 Analytical Assessment**

152 *Anthropometrical indicators* included age (years), weight (kg), BMI ( $\text{kg}/\text{m}^2$ ), WC (cm).  
153 Body composition parameters including fat mass (in % of total body weight), fat free  
154 mass, total body water, muscle mass, bone mass were measured using a Tanita-  
155 SC330S Body Composition Analyzer (Tanita Corp., Tokyo, Japan).

156 On the same blood samples, complete blood cell count, glucose, total cholesterol, high-  
157 density lipoprotein (HDL) and triglycerides were determined.

158 Physical activity of patients assessed by the number of steps measured by individual  
159 pedometers in mobile phone or by Hoffmann-La Roche's pedometers (Ltd.).

160 *Hormonal assays.* Fasting serum insulin (nU/L) was determined by immunoassay  
161 (Immunotech Insulin Irma kit, Prague, Czech Republic). Hyperinsulinemia was  
162 considered  $>12.5$  nU/L. The Homeostasis Model Assessment insulin resistance indexes  
163 (HOMA-IR) was used as surrogate measure of insulin sensitivity as follows:  $\text{HOMA-IR} =$   
164  $((\text{fasting insulin in nU/L}) \times (\text{fasting glucose in mmol/l})/22.5)$ . Insulin resistance was  
165 considered if the index was  $> 2$ .

166 **Imaging.** Ultrasound imaging (GE Vivid 7 Ultrasound; GE Healthcare Worldwide USA,  
167 Michigan) used for echocardiographic examination, and HBMD measured using Lunar  
168 Achilles Express Ultrasound densitometry (GE Healthcare USA, Madison; at normal  
169 range 100.0±15.0 Units).

170 The patients temporarily stopped taking antidiabetic and antihypertensive medications  
171 24 hours before BP measurement and blood collection to determine glucose and insulin  
172 at baseline. The standard of the American Diabetes Association (2017) was used for  
173 T2D diagnosis. [44] Hypertension was diagnosed by BP readings and from medical  
174 records. We carried out anthropometrical, laboratory, and instrumental examinations  
175 three times – before RF, after RF, and after a 30-day follow-up.

176 **2.4 Statistics** *Justification of the sample size.* The estimated treatment difference will  
177 set to 10% with a standard deviation of 8% and the superiority margin of 5% ( $\delta=0.05$ )  
178 [45] based on two-sided hypothesis testing. Using SPSS, Sample-Power, V23.0, the  
179 number of evaluable individuals needed per treatment arm  $\geq 31$ . At least 96 patients we  
180 screened and recruited, and 61 patients were assessed for eligibility in the comparative  
181 clinical trial (**Figure 1**). [46] To increase in the power of the statistical analysis and  
182 receive significant results we used two-sided Student's t tests with Bonferroni correction  
183 ( $P$ -values/2); where  $P$  values of  $<0.025$  were set as significant differences in intra  
184 groups, and  $<0.025$  between groups to compensate for the small number of patients (26  
185 in Main vs 25 in Control). The study used SPSS Statistics v23 (SPSS Inc., Illinois, USA)  
186 and Microsoft Excel-2023 with normality assessed using histograms and box plots.  
187 Given the pilot nature of the study and firm hypotheses, were used. The study data is  
188 presented in Tables as Mean  $\pm$  Standard Error of the Mean ( $M \pm SEM$ ) for normally  
189 distributed data. All analyses were intention-to-treat.

### 190 **3 RESULTS**

191 *Anthropometric results (Table 1)*. During the RF period patients in Main lost weight –  
192 8.02 kg ( $P<0.0001$ ), in Controls lost weight  $-2.67$  kg ( $P<0.025$ ); BMI in Main decreased  
193 significantly ( $P<0.0001$ ), but in Controls BMI did not significantly decrease ( $P>0.025$ ).  
194 Weight loss decreased due to fat mass in Main by  $-6.82\%$  ( $P<0.0001$ ) and in Controls  
195 by  $-1.38\%$  ( $P<0.025$ ); waist circumference in Main decreased by  $-9.36$  cm ( $P<0.0001$ ),  
196 but in Controls on  $-2.68$  cm ( $P<0.025$ ). In Main weight loss occurred due to abdominal  
197 component, and lean body mass did not significantly change in both groups.  
198 During a 30-day follow-up, Main tended to increase in weight and WC not significantly  
199 ( $P=0.19$  and  $P=0.29$ , respectively); but Controls regained weight and increased in WC  
200 even more than at baseline significantly ( $P=0.010$  and  $P<0.0015$ , respectively).  
201 *Clinical and BP results (Table 1)*. In Main SBP/DBP decreased starting from 5-7 days,  
202 and which significantly normalized at 30-day RF reaching recommended levels by the  
203 American Heart Association (2014) ( $P<0.0001$ ); in Controls SBP/DBP significantly  
204 improved, but it did not achieve to normal ranges. After a 30-day follow-up, SBP/DBP  
205 remained within normal limits in Main, but they returned to previous ranges in Controls.  
206 After 3-5 days of the ancient RF, almost all patients in Main began to produce  
207 substantial amount of sputum, which occurred periodically throughout the entire RF  
208 period; this was not observed in Controls. Patients in Main complained less about thirst,  
209 healthy comfort, and clinical symptoms during RF compared to Controls, which may be  
210 due to abstinence from eating meat and fatty foods.  
211 *Laboratory and instrumental (Table 1)*. All glycemc parameters (fasting glucose,  
212 immunoassay insulin, HOMA-IR index) in Main significantly reduced ( $P<0.0001$ ); in  
213 Controls the parameters also significantly decreased, but they did not reach normal.  
214 Lipids (cholesterol, triglyceride, HDL) significantly positive changed in Main ( $P<0.0001$ ),  
215 but in Controls the parameters did not significantly change ( $P>0.025$ ). At 30-day follow-

216 up, glycemic parameters in Main did not significantly change; in Controls they worsened  
217 as weight regained.

218 Hemoglobin in Main significantly increased from baseline at a 30-day RF ( $P<0.0001$ ),  
219 and the level was maintained at 30-day follow-up; in Controls it did not significantly  
220 change ( $P>0.025$ ).

221 *Imaging (Table 1)*. HBMD was significantly increased in Main ( $P<0.0001$ ), in Controls it  
222 did not significantly change ( $P>0.025$ ). At 30-day follow-up, HBMD in Main remained  
223 within normal limits.

224 EF in patients with HF and without HF significantly increased in Main after ancient RF  
225 ( $P<0.0001$ ), and this achievement was maintained at 30-day follow-up. The EF  
226 parameters did not significantly increase in Controls neither after modern RF nor at 30-  
227 day follow-up ( $P>0.025$ ).

228 Notably, in Main starting from 3-5 days of weight loss, it was necessary to reduce and  
229 completely stop taking the previous antidiabetic, antihypertensive, and other  
230 symptomatic medications in order to avoid hypoglycemic coma, hypotensive/hypotonic  
231 and other effects of the medications; by 6-10 days the drugs were stopped completely in  
232 Main, and at 30-day follow-up there was no evidence of T2D, hypertension, or relapse  
233 of HF. Patients in Controls could not reduce taking the previous medications, and they  
234 were receiving the same medication as at baseline.

#### 235 **4 DISCUSSION**

236 T2D and CVD are the most common non-communicable diseases and they are  
237 problematic in countries with a higher rate of overweight. [4, 6, 10, 47] RF period lasted  
238 more than 20 hours during a 30-day RF (especially in summer), and the fasting period  
239 looked like the intermittent fasting practiced by millions of adult Muslims globally for a  
240 whole lunar month every year. [35, 48, 49]

241 In this open, 60-day, controlled, single-center, randomized clinical study among 51  
242 patients with T2D in comorbidity with Hypertension, and HF (n=27), we found that  
243 significant improvements in glycemic profile, BP, lipids, EF, and HBMD were dependent  
244 on substantial weight loss. To our knowledge, this is one of the first studies to show that  
245 the different RFs may have variable treatment effects on patients with T2D and CVD.  
246 RF can have anti-hyperglycemic, antihypertensive, hypolipidemic, anti-osteoporotic  
247 effects, and restore EF, but this depends on the level of weight loss. The positive effects  
248 persisted if the weight did not return. Our study showed that when patients regained  
249 weight after a 30-day follow-up (Controls), their clinical results returned to baseline.  
250 They gained more weight and WC than baseline, and interestingly, fat mass tended to  
251 increase after the 30-day follow-up.

252 The TRF 20:4 mode allowed to maintain the achieved weight loss; they did not  
253 significantly gain weight at a 30-day follow-up and body structure also did not change. It  
254 is clinically important to maintain the achieved weight loss. Many studies evidence that  
255 TRF 20:4 allows to maintain the achieved weight loss [42, 50]

256 Obviously, great weight loss improved anabolic processes, because hemoglobin, HDL,  
257 HBMD levels significantly increased in Main. Abstinence from fatty foods and meat has  
258 an anti-osteoporosis effect and improves bone metabolism. [51, 52]

259 The study showed that patients in both groups lost weight due to a decrease in fat  
260 mass. The humans and animals studies indicated that temporal restriction diets did not  
261 induce muscle atrophy or proteolysis. [53, 54]

262 The Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy  
263 (CALERIE) phase 2 trial showed that a moderate reduction in energy intake could  
264 improve cardiometabolic health, and diabetic parameters in humans. [55, 56] Caloric  
265 restriction has been shown to extend the lifespan and health span of many animal  
266 species. [57] There has been growing interest in evaluating related strategies, such as

267 intermittent fasting, periodic fasting, and TRF may achieve the univocal benefits of RF  
268 season. [43]

269 Our study also revealed that markedly weight loss on ancient RF allowed to withdraw  
270 symptomatic drugs due to necessary to reduce and completely stop taking previous  
271 medications. Reduction to complete discontinuation of previous prescribed symptomatic  
272 medications occurred as a result of great weight loss, and we had no intention of  
273 stopping the medications. Controls was unable to reduce previous medications due to  
274 insufficient weight loss.

275 Changes in diet and fasting during the ancient RF (long-fasting hours) resulted in  
276 noticeable weight loss and may have been a type of intermittent fasting. [26-28]

277 According to our study results, the ancient RF was the same as intermittent fasting 20:4,  
278 because the patients had one meal a day. [29, 58] It was important that patients in Main  
279 strictly adhered to Ramadan's principles (the ancient RF) as "don't eat meat with don't  
280 eat fatty foods", and having only fruit meal on 'Sehri time'.

281 RF requires abstinence from water and other drinks; it's like dry fasting. Eating meat  
282 requires to drink more water, [59] so without meat patients in Main could handle the dry  
283 fasting. Indeed, Main group followed a diet in which they ate one meal a day, both  
284 during RF period and during a 30-day post-RF follow-up.

285 Overweight is a biological burden for the body, [60] and sexual self-restraint during RF  
286 also matters; because vigorous sex also reduces overall body energy and shortens life  
287 expectancy. [61-63] Most of the body metabolism is expended on the digestive and  
288 reproductive systems. [64]

289 Weight loss creates 'body potential power to weight gain' that can increase  
290 physical/mental activity, recovers from diseases, or weight regain. Individual body  
291 weight and individual limit of weight gain mode may explain the 'obesity paradox'. [65,  
292 66] The 'Obesity paradox' is driven by individual body weight and individual limit of

293 weight gain mode. This will also lead to better and more personalized treatment for  
294 patients with T2D and CVD. The ability to accumulate fat mass is one of the foundations  
295 for survival in conditions of food shortage. But, the survival rule “eat any time, any place,  
296 any opportunity” often led to overweight. Therefore, periodic RFs allowed people to stay  
297 healthy and avoid obesity-related diseases for centuries. [67, 68]

298 **Limitations.** The limitations of this study are: the study was a single-center study; this  
299 study was small and with a short follow-up duration. The strengths of this study are:  
300 Different types of RF have different effects on the health of patients with T2D and CVD  
301 and this depends on the degree of weight loss during it; both types of RF had positive  
302 effects on the patients in a randomized clinical trial; the positive results depended on  
303 maintaining the achieved weight loss during the RF. Future research should unpick the  
304 impact mechanisms of weight loss during Ramadan fasting on patients with T2D and  
305 CVD.

## 306 **5 CONCLUSION**

307 Both the RF methods allowed weight loss, but ancient RF led to markedly weight loss  
308 and significant positive change in glycemic, BP, lipids, bone mineralization, and EF in  
309 patients with T2D and CVD; the ancient RF allowed patients stopping medications. The  
310 duration of the positive results depends on the maintenance of the achieved weight  
311 loss; TRF 20:4 allows to maintain the achieved weight within 30-day follow-up.

## 312 **List of abbreviations:**

|       |                               |
|-------|-------------------------------|
| BMI   | – body mass index             |
| BP    | – blood pressure              |
| CVD   | – cardiovascular diseases     |
| EF    | – ejection fraction           |
| HbA1c | – glycosylated hemoglobin A1c |
| HBMD  | – heel bone mineral density   |
| HDL   | – high-density lipoprotein    |
| HF    | – heart failure               |



HOMA-IR – Homeostasis Model Assessment for Insulin Resistance  
M±SEM – Mean ± standard error of the mean  
NCDs – noncommunicable chronic diseases  
RF – Ramadan fasting  
SBP/DBP – systolic/diastolic blood pressure  
T2D – type two diabetes mellitus  
TRF – time-restricted feeding  
WC – waist circumference.

## **ACKNOWLEDGMENTS**

The authors thank the Diagnostic Center of University Medical Center and ANADETO Medical Center for recruiting patients, collecting data for the study, and providing technical assistance.

**Availability of data and materials.** The data are available from the authors upon reasonable request. Those wishing to request the study data should contact Principal Investigator of a research grant: Dr. Oshakbayev Kuat (Email: [kuat.oshakbayev@umc.org.kz](mailto:kuat.oshakbayev@umc.org.kz), phone + 77013999394).

**Funding sources:** This research was supported by the Ministry of Science and Higher Education of the Republic of Kazakhstan (Grant for 2023-2026 years with trial registration AP23488544) with National Center for Scientific and Technical Information of the Republic of Kazakhstan. Kuat Oshakbayev, a PI of the project, and Altay Nabiyeu are supported by University medical center for 2022-2024, and Medical Center ANADETO.

**Conflict of interest disclosures:** The authors declare that they have no competing interests (financial, professional, or personal) relevant to the manuscript. We have read and understood the journal policy on the declaration of interests and have no interests to declare. Dukenbayeva Bibazhar, the coauthor, is a director of the Medical Center 'ANADETO', who participated in the study design, data interpretation, discussion writing, bibliography, and paper review/re-review.

**Consent for publication.** All the authors of the manuscript affirm that they had access to the study data and reviewed and approved the final version.

**Author contributions:**

*KO*: study design, data collection, diagnosis, and treatment of the patients, bibliography review, statistical analysis, data interpretation, writing of the paper with re-review. *AI*: study design, data collection, preparation of statistical data in Excel, diagnosis and treatment of the patients, bibliography, and paper review. *AN*: study design, introduction and part of methods writing, data interpretation, and paper review. *KM*: data collection, data interpretation, bibliography, statistical analysis, discussion writing, and paper review. *GB*: study design, results and discussion writing, and paper review. *AD* and *NB*: data collection, data interpretation, results and discussion writing, and paper review. *BD*: study design, data collection, preparation of the statistical data in Excel, data interpretation, discussion writing, bibliography, and writing the paper with review. All the authors read and approved the final manuscript.

**Declaration of Generative AI and AI-assisted technologies in the writing process:**

During the preparation of this work the authors did not use it.

**BIBLIOGRAPHY**

- 313 1. Gaddam KK, Ventura HO, Lavie CJ. Metabolic Syndrome and Heart Failure-The Risk,  
314 Paradox, and Treatment. *Current Hypertension Reports*. 2011;13(2):142-8. doi: 10.1007/s11906-  
315 011-0179-x.
- 316 2. Blomstrand P, Sjöblom P, Nilsson M, Wijkman M, Engvall M, Länne T, et al. Overweight and  
317 obesity impair left ventricular systolic function as measured by left ventricular ejection fraction  
318 and global longitudinal strain. *Cardiovascular Diabetology*. 2018;17. doi: 10.1186/s12933-018-  
319 0756-2.
- 320 3. Haddadin F, Sud K, Estrella AM, Moctezuma S, Wu LL, Berookhim J, et al. The prevalence  
321 and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-  
322 sectional study based on the 2017 ACC/AHA guidelines. *Journal of Clinical Hypertension*.  
323 2019;21(10):1507-15. doi: 10.1111/jch.13666.
- 324 4. Akyea RK, Ntaios G, Doehner W. Obesity, metabolic health and clinical outcomes after  
325 incident cardiovascular disease: A nationwide population-based cohort study. *Journal of*  
326 *Cachexia Sarcopenia and Muscle*. 2023;14(6):2653-62. doi: 10.1002/jcsm.13340.
- 327 5. NCD NCDRFC. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes  
328 since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants (vol  
329 387, pg 1513, 2016). *Lancet*. 2017;389(10068):E2-E. doi: 10.1016/s0140-6736(16)32060-8.

- 330 6. NCD Risk Factor Collaboration (NCD-RisC)-Americas Working Group. Trends in  
331 cardiometabolic risk factors in the Americas between 1980 and 2014: a pooled analysis of  
332 population-based surveys (vol 8, pg e123, 2020). *Lancet Global Health*. 2021;9(1):E23-E. doi:  
333 10.1016/s2214-109x(20)30516-7.
- 334 7. Russo C, Jin ZZ, Homma S, Rundek T, Elkind MSV, Sacco RL, et al. Effect of diabetes and  
335 hypertension on left ventricular diastolic function in a high-risk population without evidence of  
336 heart disease. *European Journal of Heart Failure*. 2010;12(5):454-61. doi: 10.1093/eurjhf/hfq022.
- 337 8. Lumori BAE, Nuwagira E, Abeya FC, Araye AA, Masette G, Mondo CK, et al. Association of  
338 body mass index with left ventricular diastolic dysfunction among ambulatory individuals with  
339 diabetes mellitus in rural Uganda: a cross-sectional study. *Bmc Cardiovascular Disorders*.  
340 2022;22(1). doi: 10.1186/s12872-022-02718-2.
- 341 9. Baena-Díez JM, Byram AO, Grau M, Gómez-Fernández C, Vidal-Solsona M, Ledesma-Ulloa  
342 G, et al. Obesity Is an Independent Risk Factor for Heart Failure: Zona Franca Cohort Study.  
343 *Clinical Cardiology*. 2010;33(12):760-4. doi: 10.1002/clc.20837.
- 344 10. Bretzel RG. Comorbidity of diabetes mellitus and hypertension in the clinical setting: A  
345 review of prevalence, pathophysiology, and treatment perspectives. *Clinical Therapeutics*.  
346 2007;29:S35-S43. doi: 10.1016/j.clinthera.2007.07.010.
- 347 11. Jamaly S, Carlsson L, Peltonen M, Andersson-Assarsson JC, Karason K. Heart failure  
348 development in obesity: underlying risk factors and mechanistic pathways. *Esc Heart Failure*.  
349 2021;8(1):356-67. doi: 10.1002/ehf2.13081.
- 350 12. Hassanin A, Hassanein M, Lanier GM, Sadaka M, Rifaat M, Sanhoury M. Prevalence of  
351 obesity and its association with cardiometabolic risk factors, heart failure phenotype and  
352 mortality among patients hospitalized for heart failure in Egypt. *Egyptian Heart Journal*.  
353 2022;74(1). doi: 10.1186/s43044-021-00232-y.
- 354 13. Libianto R, Davis TME, Ekinçi EI. Advances in type 2 diabetes therapy: a focus on  
355 cardiovascular and renal outcomes. *Medical Journal of Australia*. 2020;212(3):133-9. doi:  
356 10.5694/mja2.50472.
- 357 14. Harborg S, Kjærgaard KA, Thomsen RW, Borgquist S, Cronin-Fenton D, Hjorth CF. New  
358 Horizons: Epidemiology of Obesity, Diabetes Mellitus, and Cancer Prognosis. *Journal of*  
359 *Clinical Endocrinology & Metabolism*. 2024;109(4):924-35. doi: 10.1210/clinem/dgad450.
- 360 15. Zhang WY, Guo X, Chen LL, Chen T, Yu JY, Wu CD, et al. Ketogenic Diets and Cardio-  
361 Metabolic Diseases. *Frontiers in Endocrinology*. 2021;12. doi: 10.3389/fendo.2021.753039.
- 362 16. Alosco ML, Spitznagel MB, Cohen R, Sweet LH, Josephson R, Hughes J, et al. Obesity and  
363 cognitive dysfunction in heart failure: The role of hypertension, type 2 diabetes, and physical  
364 fitness. *European Journal of Cardiovascular Nursing*. 2015;14(4):334-41. doi:  
365 10.1177/1474515114535331.
- 366 17. Carná Z, Osmačík P. The Effect of Obesity, Hypertension, Diabetes Mellitus, Alcohol, and  
367 Sleep Apnea on the Risk of Atrial Fibrillation. *Physiological Research*. 2021;70:S511-S25. doi:  
368 10.33549/physiolres.934744.
- 369 18. Aminian A, Wilson R, Zajichek A, Tu C, Wolski KE, Schauer PR, et al. Cardiovascular  
370 Outcomes in Patients With Type 2 Diabetes and Obesity: Comparison of Gastric Bypass, Sleeve  
371 Gastrectomy, and Usual Care. *Diabetes Care*. 2021;44(11):2552-63. doi: 10.2337/dc20-3023.
- 372 19. Galali Y, Zebari SMS, Jabbar AA, Balaky HH, Sadee BA, Hassanzadeh H. The impact of  
373 ketogenic diet on some metabolic and non-metabolic diseases: Evidence from human and animal  
374 model experiments. *Food Science & Nutrition*. 2024;12(3):1444-64. doi: 10.1002/fsn3.3873.
- 375 20. Kouvari M, Chrysohoou C, Tsiamis E, Kosyfa H, Kalogirou L, Filippou A, et al. The  
376 "overweight paradox" in the prognosis of acute coronary syndrome for patients with heart  
377 failure-A truth for all? A 10-year follow-up study. *Maturitas*. 2017;102:6-12. doi:  
378 10.1016/j.maturitas.2017.05.003.
- 379 21. Marzona I, Avanzini F, Lucisano G, Tettamanti M, Baviera M, Nicolucci A, et al. Are all  
380 people with diabetes and cardiovascular risk factors or microvascular complications at very high

- 381 risk? Findings from the Risk and Prevention Study. *Acta Diabetologica*. 2017;54(2):123-31. doi:  
382 10.1007/s00592-016-0899-0.
- 383 22. Prakoso AT, Wahyono TYM, Sibarani RP. Body Mass Index and Risk for Hypertension of  
384 Adults with Type 2 Diabetes Mellitus Body Mass Index and Risk for Hypertension of Adults  
385 with Type 2 Diabetes Mellitus. *Journal of Pharmaceutical Negative Results*. 2022;13:843-7. doi:  
386 10.47750/pnr.2022.13.S03.128.
- 387 23. Kanazawa I, Takeno A, Tanaka K, Yamane Y, Sugimoto T. Osteoporosis and vertebral  
388 fracture are associated with deterioration of activities of daily living and quality of life in patients  
389 with type 2 diabetes mellitus. *Journal of Bone and Mineral Metabolism*. 2019;37(3):503-11. doi:  
390 10.1007/s00774-018-0948-6.
- 391 24. Kong XK, Xie R, Zhang D, Chen XJ, Wang XF, Lu JL, et al. Association of cardiovascular  
392 disease prevalence with BMD and fracture in men with T2DM. *Journal of Diabetes*. 2024;16(4).  
393 doi: 10.1111/1753-0407.13530.
- 394 25. Kim H, Lee HYJ. Risk of Stroke and Cardiovascular Disease According to Diabetes Mellitus  
395 Status. *Western Journal of Nursing Research*. 2023;45(6):520-7. doi:  
396 10.1177/01939459231158212.
- 397 26. Mazidi M, Rezaie P, Chaudhri O, Karimi E, Nematy M. The effect of Ramadan fasting on  
398 cardiometabolic risk factors and anthropometrics parameters: A systematic review. *Pakistan*  
399 *Journal of Medical Sciences*. 2015;31(5):1250-5. doi: 10.12669/pjms.315.7649.
- 400 27. Ismail AA, Megallaa MH, Badrah MH, Farghaly MAA. Study of the metabolic effects of  
401 Ramadan fasting on patients with type 2 diabetes. Relation to glycemic control, hypoglycemic  
402 events and diabetic complications. *Clinical Diabetology*. 2021;10(2):161-8. doi:  
403 10.5603/DK.a2020.0004.
- 404 28. Tsitsou S, Zacharodimos N, Poulia KA, Karatzi K, Dimitriadis G, Papakonstantinou E.  
405 Effects of Time-Restricted Feeding and Ramadan Fasting on Body Weight, Body Composition,  
406 Glucose Responses, and Insulin Resistance: A Systematic Review of Randomized Controlled  
407 Trials. *Nutrients*. 2022;14(22). doi: 10.3390/nu14224778.
- 408 29. Oueslati I, Kardi A, Boukhayatia F, Hammami B, Cheikh M, Ben Romdhane N, et al. Impact  
409 of Ramadan intermittent fasting on metabolic and inflammatory profiles in type 2 diabetic  
410 patients. *Journal of Diabetes and Metabolic Disorders*. 2022;21(1):751-8. doi: 10.1007/s40200-  
411 022-01046-8.
- 412 30. Bakhotmah B. [The puzzle of self-reported weight gain in a month of fasting (Ramadan)  
413 among a cohort of Saudi families in Jeddah, Western Saudi Arabia]. *NUTRITION*  
414 *JOURNAL*2011.
- 415 31. Sulaiman S, Tsiga-Ahmed F, Faris M, Musa M, Akpan U, Umar A, et al. [Nigerian Muslim's  
416 Perceptions of Changes in Diet, Weight, and Health Status during Ramadan: A Nationwide  
417 Cross-Sectional Study]. *INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH*  
418 *AND PUBLIC HEALTH*2022.
- 419 32. Goh KG, Zakaria MH, Azwan RNR, Singh KKB, Hisham MHB, Hussein Z. Effect of  
420 empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia,  
421 and hypoglycaemia. *Diabetes & Metabolic Syndrome-Clinical Research & Reviews*. 2023;17(1).  
422 doi: 10.1016/j.dsx.2022.102680.
- 423 33. Pathan MF, Akter N, Selim S, Saifuddin M, Qureshi NK, Kamrul-Hasan ABM, et al.  
424 Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During  
425 Ramadan: A Real-World Study from Bangladesh. *Diabetes Metabolic Syndrome and Obesity-*  
426 *Target & Therapy*. 2022;15:4011-21. doi: 10.2147/dmso.s380544.
- 427 34. Ibrahim A, Ghaleb R, Mansour H, Hanafy A, Mahmoud NM, Elsharef MA, et al. Safety and  
428 Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With  
429 Decompensated Heart Failure and Reduced Ejection Fraction. *Frontiers in Cardiovascular*  
430 *Medicine*. 2020;7. doi: 10.3389/fcvm.2020.602251.
- 431 35. Mohamed YA, Abouelmagd M, Elbially A, Elwassefy M, Kyrillos F. Effect of intermittent  
432 fasting on lipid biokinetics in obese and overweight patients with type 2 diabetes mellitus:

- 433 prospective observational study. *Diabetology & Metabolic Syndrome*. 2024;16(1). doi:  
434 10.1186/s13098-023-01234-3.
- 435 36. Oshakbayev K, Dukenbayeva B, Togizbayeva G, Durmanova A, Gazaliyeva M, Sabir A, et  
436 al. Weight loss technology for people with treated type 2 diabetes: a randomized controlled trial.  
437 *Nutrition & Metabolism*. 2017;14. doi: 10.1186/s12986-017-0163-9.
- 438 37. Oshakbayev K, Bimbetov B, Maneknova K, Bedelbayeva G, Mustafin K, Dukenbayeva B.  
439 Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy  
440 in a randomized clinical trial. *Current Medical Research and Opinion*. 2019;35(1):157-65. doi:  
441 10.1080/03007995.2018.1547696.
- 442 38. Oshakbayev K, Durmanova A, Zhankalova Z, Idrisov A, Bedelbayeva G, Gazaliyeva M, et  
443 al. Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial.  
444 *Scientific reports*. 2024;14(1):10979-. doi: 10.1038/s41598-024-61703-1.
- 445 39. Hosseini E, Ammar A, Josephson J, Gibson D, Askari G, Bragazzi N, et al. [Fasting diets:  
446 what are the impacts on eating behaviors, sleep, mood, and well-being?]. *FRONTIERS IN*  
447 *NUTRITION*2024.
- 448 40. Pérez-Lloréns J, Acosta Y, Brun F. [Seafood in Mediterranean countries: A culinary journey  
449 through history]. *INTERNATIONAL JOURNAL OF GASTRONOMY AND FOOD*  
450 *SCIENCE*2021.
- 451 41. Tieman M, Hassan F. [Convergence of food systems: Kosher, Christian and Halal].  
452 *BRITISH FOOD JOURNAL*2015. p. 2313-27.
- 453 42. Welton S, Minty R, O'Driscoll T, Willms H, Pokier D, Madden S, et al. [Intermittent fasting  
454 and weight loss Systematic review]. *CANADIAN FAMILY PHYSICIAN*2020. p. 117-25.
- 455 43. Crupi AN, Haase J, Brandhorst S, Longo VD. Periodic and Intermittent Fasting in Diabetes  
456 and Cardiovascular Disease. *Current Diabetes Reports*. 2020;20(12). doi: 10.1007/s11892-020-  
457 01362-4.
- 458 44. Khunti K, Alsifri S, Aronson R, Berkovic MC, Enters-Weijnen C, Forsen T, et al. Impact of  
459 hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people  
460 with type 1 and insulin-treated type 2 diabetes. *Diabetes Research and Clinical Practice*.  
461 2017;130:121-9. doi: 10.1016/j.diabres.2017.05.004.
- 462 45. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients  
463 treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical  
464 trials. *American Journal of Clinical Nutrition*. 2004;80(6):1461-8. doi: 10.1093/ajcn/80.6.1461.
- 465 46. Hickey GL, Grant SW, Dunning J, Siepe A. Statistical primer: sample size and power  
466 calculations-why, when and how? *European Journal of Cardio-Thoracic Surgery*. 2018;54(1):4-  
467 9. doi: 10.1093/ejcts/ezy169.
- 468 47. Triposkiadis F, Xanthopoulos A, Bargiota A, Kitai T, Katsiki N, Farmakis D, et al. Diabetes  
469 Mellitus and Heart Failure. *Journal of Clinical Medicine*. 2021;10(16). doi:  
470 10.3390/jcm10163682.
- 471 48. Lessan N, Ali T. Energy Metabolism and Intermittent Fasting: The Ramadan Perspective.  
472 *Nutrients*. 2019;11(5). doi: 10.3390/nu11051192.
- 473 49. Fernando HA, Zibellini J, Harris RA, Seimon RV, Sainsbury A. Effect of Ramadan Fasting  
474 on Weight and Body Composition in Healthy Non-Athlete Adults: A Systematic Review and  
475 Meta-Analysis. *Nutrients*. 2019;11(2). doi: 10.3390/nu11020478.
- 476 50. St-Onge M, Ard J, Baskin M, Chiuve S, Johnson H, Kris-Etherton P, et al. [Meal Timing and  
477 Frequency: Implications for Cardiovascular Disease Prevention: A Scientific Statement From the  
478 American Heart Association]. *CIRCULATION*2017. p. E96-E121.
- 479 51. Rodopaios N, Manolarakis G, Koulouri A, Vasara E, Papadopoulou S, Skepastianos P, et al.  
480 [The significant effect on musculoskeletal metabolism and bone density of the Eastern  
481 Mediterranean Christian Orthodox Church fasting]. *EUROPEAN JOURNAL OF CLINICAL*  
482 *NUTRITION*2020. p. 1736-42.
- 483 52. Peng Y, Zhong Z, Huang C, Wang W. [The effects of popular diets on bone health in the past  
484 decade: a narrative review]. *FRONTIERS IN ENDOCRINOLOGY*2024.



- 485 53. Savitikadi P, Gogulothu R, Ismail A, Reddy GB, Reddy VS. Combined prenatal to postnatal  
486 protein restriction augments protein quality control processes and proteolysis in the muscle of rat  
487 offspring. *Journal of Nutritional Biochemistry*. 2023;114. doi: 10.1016/j.jnutbio.2023.109273.
- 488 54. Pearson AG, Alexander L, Witard OC, Coughlin TE, Tipton KD, Walshe IH. A  
489 hypoenergetic diet with decreased protein intake does not reduce lean body mass in trained  
490 females. *European Journal of Applied Physiology*. 2021;121(3):771-81. doi: 10.1007/s00421-  
491 020-04555-7.
- 492 55. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, et al. Effect  
493 of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative  
494 stress in overweight individuals: A randomized controlled trial (vol 295, pg 1539, 2006). *Jama-*  
495 *Journal of the American Medical Association*. 2006;295(21):2482-.
- 496 56. Mendelsohn AR, Larrick JW. Dietary Restriction: Critical Co-Factors to Separate Health  
497 Span from Life Span Benefits. *Rejuvenation Research*. 2012;15(5):523-9. doi:  
498 10.1089/rej.2012.1371.
- 499 57. Mattison JA, Colman RJ, Beasley TM, Allison DB, Kemnitz JW, Roth GS, et al. Caloric  
500 restriction improves health and survival of rhesus monkeys. *Nature Communications*. 2017;8.  
501 doi: 10.1038/ncomms14063.
- 502 58. Aydin E, Aydin S, Gul M, Yetim M, Demir M, Ozkan C, et al. Influence of Intermittent  
503 Fasting During Ramadan on Circadian Variation of Symptom-Onset and Prehospital Time Delay  
504 in Acute ST-Segment Elevation Myocardial Infarction. *Angiology*. doi:  
505 10.1177/00033197221114087.
- 506 59. Vanham D, Gawlik B, Bidoglio G. [Food consumption and related water resources in Nordic  
507 cities]. *ECOLOGICAL INDICATORS*2017. p. 119-29.
- 508 60. Dirinck EL, Dirtu AC, Govindan M, Covaci A, Van Gaal LF, Jorens PG. Exposure to  
509 Persistent Organic Pollutants: Relationship With Abnormal Glucose Metabolism and Visceral  
510 Adiposity. *Diabetes Care*. 2014;37(7):1951-8. doi: 10.2337/dc13-2329.
- 511 61. Salomon TB, Benfato MS. Sexual activity affects the redox profile along the aging process in  
512 male rats. *Biogerontology*. 2018;19(1):13-21. doi: 10.1007/s10522-017-9731-7.
- 513 62. Jasienska G, Bribiescas RG, Furberg A-S, Helle S, Nunez-de la Mora A. Human  
514 reproduction and health: an evolutionary perspective. *Lancet*. 2017;390(10093):510-20. doi:  
515 10.1016/s0140-6736(17)30573-1.
- 516 63. Kirecci SL, Albayrak AT, Yavuzsan AH, Yesildal C, Ilgi M, Kutsal C. Sexual intercourse  
517 before exercise has a detrimental effect on lower extremity muscle strength in men. *Postgraduate*  
518 *Medical Journal*. 2022;98(1161). doi: 10.1136/postgradmedj-2020-139033.
- 519 64. Ellison PT. Energetics and reproductive effort. *American Journal of Human Biology*.  
520 2003;15(3):342-51. doi: 10.1002/ajhb.10152.
- 521 65. Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ. Obesity paradox  
522 in cardiovascular disease: where do we stand? *Vascular Health and Risk Management*.  
523 2019;15:89-100. doi: 10.2147/vhrm.s168946.
- 524 66. Salvestrini V, Sell C, Lorenzini A. Obesity May Accelerate the Aging Process. *Frontiers in*  
525 *Endocrinology*. 2019;10. doi: 10.3389/fendo.2019.00266.
- 526 67. Gribsholt SB, Cronin-Fenton D, Veres K, Thomsen RW, Ording AG, Richelsen B, et al.  
527 Hospital-diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort study.  
528 *Journal of Internal Medicine*. 2020;287(4):435-47. doi: 10.1111/joim.13013.
- 529 68. Gielen M, Hageman GJ, Antoniou EE, Nordfjall K, Mangino M, Balasubramanyam M, et al.  
530 Body mass index is negatively associated with telomere length: a collaborative cross-sectional  
531 meta-analysis of 87 observational studies. *American Journal of Clinical Nutrition*.  
532 2018;108(3):453-75. doi: 10.1093/ajcn/nqy107.

## Figure legends

Figure 1. Participant CONSORT Flow Diagram

The Ramadan fasting weight loss in patients with type two diabetes, Hypertension, and with Heart failure: a randomized clinical trial



**Table 1** Anthropometrical data, body composition, blood pressure, glucose and lipid metabolism, HBMD, and EF in Main (n=26) and Controls (n=25) at baseline, after RF, and 30-day follow-up (M±SEM).

| Variables                         | Main group, n=26 |                 |                        | Control group, n=25       |                             |                            |
|-----------------------------------|------------------|-----------------|------------------------|---------------------------|-----------------------------|----------------------------|
|                                   | Baseline         | After 30-day RF | After 30-day follow-up | Baseline                  | After 30-day RF             | After 30-day follow-up     |
| Weight (kg)                       | 81.91 ± 0.68     | 73.89 ± 0.73**  | 75.27 ± 0.74           | 80.88 ± 0.69              | 78.21 ± 0.71* <sup>#</sup>  | 80.97 ± 0.70 <sup>‡#</sup> |
| Fat mass (%)                      | 28.79 ± 0.41     | 21.97 ± 0.39**  | 22.73 ± 0.40           | 28.23 ± 0.39              | 26.85 ± 0.37* <sup>#</sup>  | 28.79 ± 0.39 <sup>‡#</sup> |
| Fat free mass (%)                 | 53.14 ± 0.45     | 52.02 ± 0.45    | 52.56 ± 0.44           | 53.16 ± 0.44              | 52.96 ± 0.45                | 53.11 ± 0.44               |
| BMI (kg/m <sup>2</sup> )          | 29.06 ± 0.32     | 26.21 ± 0.31**  | 26.70 ± 0.31           | 28.42 ± 0.29              | 27.48 ± 0.31 <sup>#</sup>   | 28.45 ± 0.30 <sup>#</sup>  |
| Waist circumference (cm)          | 97.29 ± 0.53     | 87.93 ± 0.52**  | 88.72 ± 0.53           | 96.65 ± 0.53              | 93.97 ± 0.54* <sup>#</sup>  | 96.68 ± 0.54 <sup>‡#</sup> |
| Systolic blood pressure (mmHg)    | 157.21 ± 1.19    | 125.84 ± 1.12** | 127.25 ± 1.13          | 155.69 ± 1.21             | 148.82 ± 1.02* <sup>#</sup> | 151.36 ± 1.18 <sup>#</sup> |
| Diastolic blood pressure (mmHg)   | 98.57 ± 0.83     | 79.24 ± 0.86**  | 78.58 ± 0.85           | 97.18 ± 0.89              | 93.73 ± 0.90* <sup>#</sup>  | 95.29 ± 1.10 <sup>#</sup>  |
| Hemoglobin (g/L)                  | 124.36 ± 0.72    | 138.66 ± 0.79** | 138.82 ± 0.75          | 125.22 ± 0.76             | 126.68 ± 0.78 <sup>#</sup>  | 126.21 ± 0.77 <sup>#</sup> |
| Fasting glucose (mmol/L)          | 13.94 ± 0.22     | 5.25 ± 0.11**   | 5.19 ± 0.13            | 12.95 ± 0.20              | 10.22 ± 0.18* <sup>#</sup>  | 11.86 ± 0.18 <sup>‡#</sup> |
| Immunoassay Insulin (nU/L)        | 19.96 ± 0.58     | 8.12 ± 0.31**   | 8.08 ± 0.38            | 18.71 ± 0.52              | 16.72 ± 0.49* <sup>#</sup>  | 17.22 ± 0.50 <sup>#</sup>  |
| HOMA-IR index                     | 12.37 ± 0.34     | 1.89 ± 0.14**   | 1.86 ± 0.21            | 10.77 ± 0.31 <sup>#</sup> | 7.59 ± 0.27* <sup>#</sup>   | 9.08 ± 0.27 <sup>‡#</sup>  |
| Cholesterol (mmol/L)              | 5.85 ± 0.08      | 4.97 ± 0.08**   | 5.01 ± 0.09            | 5.81 ± 0.08               | 5.58 ± 0.09 <sup>#</sup>    | 5.61 ± 0.09 <sup>#</sup>   |
| Triglyceride (mmol/L)             | 2.66 ± 0.06      | 1.83 ± 0.04**   | 1.78 ± 0.05            | 2.68 ± 0.06               | 1.93 ± 0.06                 | 2.06 ± 0.06 <sup>#</sup>   |
| High density lipoprotein (mmol/L) | 0.94 ± 0.03      | 1.61 ± 0.03**   | 1.89 ± 0.03            | 0.95 ± 0.03               | 1.05 ± 0.04 <sup>#</sup>    | 1.18 ± 0.04 <sup>#</sup>   |
| HBMD (Unit)                       | 81.77 ± 1.76     | 92.73 ± 1.71*   | 93.31 ± 1.92           | 82.05 ± 1.89              | 84.74 ± 1.90 <sup>#</sup>   | 84.21 ± 1.90 <sup>#</sup>  |
| EF with HF (%), n=14 in Main:     | 48.93 ± 0.48     | 58.31 ± 0.49**  | 59.61 ± 0.49           |                           |                             |                            |

|                                  |              |                           |              |              |                           |                           |
|----------------------------------|--------------|---------------------------|--------------|--------------|---------------------------|---------------------------|
| n=13 in Controls:                |              |                           |              | 49.61 ± 0.49 | 50.94 ± 0.47 <sup>#</sup> | 51.25 ± 0.47 <sup>#</sup> |
| EF without HF (%), n=12 in Main: | 63.52 ± 0.68 | 67.46 ± 0.71 <sup>*</sup> | 66.75 ± 0.72 |              |                           |                           |
| n=12 in Controls:                |              |                           |              | 64.55 ± 0.56 | 65.13 ± 0.63 <sup>#</sup> | 63.81 ± 0.63 <sup>#</sup> |

\*  $P < 0.025$ , and \*\*  $P < 0.0001$  were set as significant from baseline in the same group;

‡  $P < 0.025$  was set as significant between periods “After 30-day RF” and “After 30-day follow-up” in the same group;

#  $P < 0.025$  was considered as significant differences between Main and Controls in the corresponding parameters.

*Abbreviations:* BP, blood pressure; EF, ejection fraction; HBMD, heel bone mineral density; HF, heart failure; HOMA-IR, Homeostasis Model Assessment for Insulin Resistance; M, mean; RF, Ramadan fasting; SEM, standard error of the mean.